Randomized pilot trial of rapamycin for ovarian aging in women; results not reported
A prospective, randomized, double-blind, placebo-controlled pilot study was proposed to assess whether low-dose rapamycin could delay ovarian aging in women. Animal studies had suggested rapamycin might slow or reverse age-associated pathways. No results, sample size, or effect sizes were reported in the abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 26, 2025 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Women
- Primary outcome
- Ability of low-dose rapamycin to delay ovarian aging in women
- Effect size
- —
- Significance
- Not reported
- Journal
- Columbia University
- Published
- Dec 26, 2025
Sources
Primary source
- Columbia University ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.